Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04677712 · ClinicalTrials.gov registry record · Phase 4
Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite
A Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
NCT04677712: Completed Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT04677712 is a Phase 4 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04677712, a Phase 4 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study will investigate treatments that may mitigate bruising after QWO™ (Collagenase clostridium histolyticum \[CCH\]-aaes) treatment of cellulite in the buttocks.
Interventions
- DRUG CCH-aaes
- OTHER Compression
- OTHER Cold Packs
- DRUG Arnica Gel
- DRUG INhance®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04677712
The ClinicalTrials.gov registry entry for NCT04677712 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CCH-aaes is the first listed.
NCT04677712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04677712 about?
NCT04677712 is a clinical study titled "Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite". This study will investigate treatments that may mitigate bruising after QWO™ (Collagenase clostridium histolyticum \[CCH\]-aaes) treatment of cellulite in the buttocks.
What is the current status of trial NCT04677712?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2020-12-28. Estimated completion is 2021-09-02.
What interventions are being tested in trial NCT04677712?
The interventions under investigation include: CCH-aaes (DRUG), Compression (OTHER), Cold Packs (OTHER), Arnica Gel (DRUG), INhance® (DRUG).
Who is sponsoring clinical trial NCT04677712?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.